Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ARVN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Arvinas Inc

ARVN
Current price
8.23 USD +0.22 USD (+2.68%)
Last closed 8.02 USD
ISIN US04335A1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 580 281 600 USD
Yield for 12 month -68.65 %
1Y
3Y
5Y
10Y
15Y
ARVN
21.11.2021 - 28.11.2021

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

19.36 USD

P/E Ratio

Dividend Yield

Financials ARVN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+263 400 000 USD

Last Year

+78 500 000 USD

Current Quarter

+188 800 000 USD

Last Quarter

+59 200 000 USD

Current Year

+256 800 000 USD

Last Year

+78 500 000 USD

Current Quarter

+188 800 000 USD

Last Quarter

+57 600 000 USD
EBITDA -91 400 000 USD
Operating Margin TTM 37.82 %
Price to Earnings
Return On Assets TTM -5.39 %
PEG Ratio
Return On Equity TTM -7.34 %
Wall Street Target Price 19.36 USD
Revenue TTM 426 900 000 USD
Book Value 9.04 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 646.20 %
Dividend Yield
Gross Profit TTM 426 900 000 USD
Earnings per share -0.66 USD
Diluted Eps TTM -0.66 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -10.92 %

Stock Valuation ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 17.70
Enterprise Value Revenue 5.69
Price Sales TTM 1.36
Enterprise Value EBITDA -1.62
Price Book MRQ 0.87

Technical Indicators ARVN

For 52 Weeks

5.90 USD 34.11 USD
50 Day MA 7.41 USD
Shares Short Prior Month 7 730 211
200 Day MA 16.24 USD
Short Ratio 3.77
Shares Short 8 325 671
Short Percent 11.59 %